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Can~r is one of the most imp<>rtant medical problems in today' s world and in Malaysia it is one of the 
leading causes of death.Although development of cancer takes a considerable amount of man's life span, it 
is however possible to detect its early pre-cancerous stage.Death due to cancer may be avoided if detected 
early and this is usually done by biochemical measurement of tumour markers. 
Tumour ~Iarkers are substances which are related to the presence or progress of a tumour (1 ). 
They inclu_de proteins such as enzymes and peptides which are secreted into body fluids by tumours and 
antigens vihich are expressed on cell surfaces.In contrast, tumour markers also play a critical role in the 
monitoring and treatment of patients with cancer . (2) 
The method employed for thi~ preliminary/pilot study is based on ELISA technique .. The CA 125 enzyme 
immunoassay kit was purchased from TECO USA which uses a monoclonal antibody .. It is specific for 
surface antigen derived fi·om a papillary serous cyst adenocarcinoma. Elevated CA 125 serum levels are 
also found in patient with serious endometrium and fallopian tube. 
The CA 15.3 enzyme immunoassay test kit was purchased from TECO USA which uses monoclonal 
antibodies to detect two antigenic sites associated with breast carcinoma cells.CA 15.3 is also useful for 
serial monitoring . 
The presence of tumour calls in the blood can mean different things depending on the stage of the disease . 
. If tumour cells are found in the blood ,most likely it indicates a metastasis of the primary tumour. 
The presenc-e of these cells in more advanced stages may indi<:ate a more rapidly progressing disease. 
Objedive 
The objective of this prellminary/pilot study is : 
t.To fmd if serum CA 12~ and 15.3 are specific and sensitive tumour mark~s for ovarian and breast cancer 
respectively during screerung. · 
1 
Us~fuln~ss of serum CA1:25 
Currently the only tumour marker to have a well defined and validated role in the management of ovarian 
cancer is CA125. 
Changes in the level ofCA125 can be used as a reliable indication of response to progression according to 
various criteria but it does not yet have a clear place in diagnosis or prognosis. 
CA125,a large glycoprotein ofun.lmown functions is the most extensively researched tumour markers to be 
identified for epithelial ovaria1"1 cancer. 
The serum concentration of CA125 is elevated by the vascular invasion, tissue destruction and infJalll.t-nation 
associated with maligna.t"1t disease and is elevated in over 90% of those women with advanced ovarian 
cancer(Tuxen et a111995) and 40% of all patients with advanced intra-abdominal malignancy . 
Levels can also be elevated during menstruation or pregnancy and in other benign conditions such as 
endometriosis, peritonitis or cirrhosis, particularly with ascites. 
Usefu~11ess of serum CA15.3 
There are a number of tumour markers that can help clinicians to identify and diagnose which breast cancer 
patients will have aggressive disease and which will have an indolent course. These markers include 
e;troaen and progesterone receptors~ DNA ploidy and percent-S phase profile ,epidermal growth factor 
recep~ar ,HER-2/neu oncogene, p53 tumour suppresser gene, cathepsin D., proliferation markers and 
CA15.3. 
CAI5.3 is most useful for monitoring patients post-operatively for recurrence, particularlymetatastic 
diseases ( 4) . 96% of pati-ents :v1th local a?d sy~temic ha~~ eleva~ed .CA15.3 , which can be 
used to predict recurrence earl1er than radJ01ogical and clmical cntena. · 
A 25% increase in the :entm ~AJ5_3 i~:~ associated with pror;ression of car-ch1oma.{4). A 50%. ilecrr.ar.e b 
. . ~· ·;, 1· .:... :; is associated wtth response to treatment. seiUIU v .. "'· 
2 
I 
1 
JMETHOOOLOGY 
Patients 
Since the establishment of the tumour marker unit at the Dept. of chemical Pathology in April 2000 about 
91 blood specimen belong to patients from various wards such as Oncology ,O&G, Medical ,SOPD clinic 
and l:'ladiotheraphy unit were received by the department .. Most request form were diagnosed as ovarian 
and breast cancer without other relevant information such as confirmatory benign or malignant 
stage(histology diagnosis report). 
A study to establish nonnal valu~ ofCA125 and CAl 53 among local Kelantanese healthy subject were also 
conducted (N=17 ).(Table 7 and 8 ). Their blood sample were collected and allowed to clot1 
spinned,separated and the serum were stored at -20 C. 
Total number of patients screened for serum CA125 is 56 w~I~ for serum CAl 53 is 35. 
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Measurement of Serum CA125 and CA 153 
Both serum CA125 and CA15.3 were analysed using ELISA Kits purchased from TECO 
USA.( Attachment land 2) 
The results were confirmed using Tumour Marker Control (Lyphochek) BIO RAD USA.(Attachment 3 ) 
ENZYl\IIE LINKED IM:MUNOABSORBENT ASSAY (ELISA) 
Enzyme linked immunoabsorbent assay (ELISA) is a heterogeneous assay which is similar to the 
immunoradiometric assay except that an enzyme tag is attached to the antibody instead of a radioactive 
label. This assay has the advantage of avoiding radioactive materials and produces an end product that can 
be measured in a spectrophotometer. The antigen which is being studied is bound to the enzyme-labelled 
antibody and the excess antibody is removed. 
Then the s~cond antibody containing the enzyme is added followed by the substrate and cofactors 
necessary for visualization of enzyme activity. The amount of antigen present is directly related to the 
amount of enzymatic activity (substrate formed ) during a detection incubation period. The sensitivity of 
the assay may be increased by increasing the incubation time for producing substrate. 
In some cases, substrate formed may give an optical color change so that the detection of the tumour 
marker being measured can be determined by special reader that can identify the slight chances in color. 
This kind of special reader are called "microplate reader''(6). 
CA125- Principle Of The Test EUSA Kit ( 5 ) 
The Ca 125 ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The 
assay system utilizes a monoclonal antibody directed against a distinct antigenic determinant on the intact 
CA125 molecule is used for solid phase immobilization (on the microtiter walls). A rabbit Anti -CA125 
antibody conjugated to hoseradish peroxidase (HRPO ) is in the antibody -enzyme conjugate solution. The 
test sample is allowed to react simultaneously with the two antibodies,resulting in the CA125 molecules 
being sandwiched between the solid phase and enzyme-linked antibodies. 
After 3 ~hour incubation at 3 7 C ,the wells are washed with water to remove unbound labelled antibodies. 
A solution ofH2021TI\1B is added and incubated for 20 minutes, resulting in the development of a blue 
colour. The color development is stopped with the addition of 3 N HCL changing the color to yellow. 
The concentration ofCAI25 is directly pr~portional to the color intensity of the test sample. 
Absorbance is measured spectrophotometncally at 450nm. 
4 
CAl 53- Principle Of The Test ELISA Kit (4) 
The Cal 53 ELISA test kit is based on the principle of a solid phase enzyme-linked immunosorbent 
assay.The assay system utilizes a monoclonal antibody directed against a distinct antigenic determinant on 
the intact CAl 53 molecule used for solid phase immobilization ( on the microtiter walls ).A rabbit anti-
CAl 53 antibody conjugated to horsedish peroxidase (HRPO) is in the antibody _enzyme conjugate 
solution. The test sample is allowed to react sequentially with the two antibodies ,resulting in the CAl 53 
molecules being sandwiched between the solid phase and enzyme linked antibodies. After two separate 1 
hr incubation steps at 3 7 C ,the wells are washed with water to remove unbound labeled antibodies. A 
solution ofH202/TMB is added and incubated for 20 minutes ,resulting in the development of a blue color. 
The color development is stopped with the addition of 3N HCL changing the color to yellow. The 
concentratJon of CAl 53 is directly proportional to the color intensity of the test sample. Absorbance is 
measured spectrophotometrically at 450 nm. 
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R"ESULTS 
Table 1 : Normal Serum CAI25 value at Diagnosis.(<35IU/ml) 
No Patient Diagnosis CA125 vVad Age Race Histopath 
At Diagnosis Report. 
1. sz Ovarian Tumour 20.5 3s 33 ~~ c=confirmed Ca. 
2. SY Rt. Ovarian Cyst 2.32 ls M 
3. SY Lt. Ovarian Cyst 2.19 ts :tv! c 
4. ~ Granular Cyst 12.7 RT 30 M c 
5. RA Ca. Ovary 18.6 0/G 1\-l c 
6. CKCI Ovarian Mass 14.5 2s 24 M c 
7. 1\t!O Ovarian Tumour 11.3 0/G 60 M c 
8. SAY Post R.Cophorectomy 1.9 Gynae 17 M c 
9. NH Ovarian Cyst 26.4 ls 18 M c 
10. SIUvi Ovarian Cyst 14.0 ls 47 M c 
11. CKCI Ovarian Tumour 15.5 2s 24 ~1 
12. IiH 1-l.!olar Pregnancy 2.37 2s 36 M 
13. SR1vl Ovaraian Cyst 14.0 47 M 
14. :NH Ovarian Cyst 5.9 5TB 12 M 
15. MIN TRO l-llalignancy 10.6 0/G 28 M 
16. NHAK Ovarian !Yfuss 15.4 ls 18 ~I 
17. CH RIF Pain 3.4 3u M 
18. KELD Ovarian Cyst 5.9 Is 64 M 
19. ZHM Ovarian Cn 11..1 O&G 44 Ivl 
20. M.L\.10* Ovarian Tumour 8.4 O&G 61 rvi 
21. NtJl\.1Y Ovarian Tumour 10.5 O&G 31 M 
22. A9709560varian Tumour 15.6 O&G 32 M 
23. NMS Ovarian TU.mour 8.2 O&G 50 ~~ 
24. ZI Ovarian Cyst 
0 31.2 O&G ~I 
25. KELD 5.9 O&G 64 M 
26. FC OvarianCa 24.0 lU c 
27. MSI Dysplasia Polyp 2.5 3U h-1 
28. 1-llvi Ovarian Cyst 2.6 IU ?vi 
29. ZM Ovarian Cyst 6.0 lU ?vi 
30. PUS Endometrioses 
2.4 O&G 40 Ivi 
31. ROA Ovarian Tumour 2.4 lU M 
32. NOR Ca Breast(Chemo) 26.8 RT lv! 
33. NIS Uterine ~lfass 
25.2 lS 34 M 
34. S1VlH Chondrosarcoma 
7.9 4U M 
Statistic Report: 
Total Screening: N=56 . . . 34~100156 = 34 (60.7%) with vanous form ofovanan disease. 
Corfirmed Cancer (Histopath Report ) 
N ==56 · 1 · SxlOOiS6 = 8 (l4.3%) conlli"'"D'led to have ovartan tumour, carcmom~. 
,, l/ 
..,, . . .· th Iep ~ uul. a·.,.·ww lv . 
.. ...:.: .Lu~~Uj-1'~ ~~ 
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Table2 : Serum CA 125 Value Above Cut-Off Value (>35 IU/ml) 
No. Patient Diagnosis CA125 \Vad Ag~ Race Histopath. 
Report. 
At Diagnosis 
1. \VZY Ovarian Tumour 53.1 0/G 57 M c 
2. MJA Ca Ovary >400.0 Is 76 ~1 c 
3. SM Screening Ovary Ca 56.4 RT 28 ~! c 
4. RZ 
-
Ovarian Ca 103 RT 32 lvf c 
5. SBH Cx.Ca 70.7 3s M 
6. RAH Ovarian Tumour 124.0 1s 17 M 
7. NII Ca Ovary 124.9 0/G 30 M 
8. Zl\I Ovarian Tumour 101.6 ls 23 l\tl c 
9. NR Ca. Cervix 465.5 Is M -
10. ss Ovarian Cyst 85.4 RT 24 M c 
11. NIA Ovarian Cyst 94.1 0/G 45 ~I 
12. sm CaOvary 45.1 Is ~1 
13.* ROI Uterine Fibroid 100.0 Is 40 lvf 
]4. WA 467.8 Is 76 !Yl 
15. ANS Ca Colorectal 170 RT 26 M 
16. WZY Ovarian Tumour 100.8 . O&G 67 M 
17. NS Ovarian Tumour 40.4 Is 53 M 
18. SI Ca Ovary 62.2 lS 61 M 
19. CYCM Malignancy Renal >400.0 IU :rvr 
20. TR Ovarian Cyst 83.7 IS M 
21. CFCA Ca Ovary >400.0 ONCO 57 Ivf 
22. RAS Ovarian Ca 198.1 1U 25 M 
Statistic Report: 
N=56 
22xl00/56 = 22(39.2%) 
Correlation with Histopath Report -Confirmed Ca 
7xi00/56 = 7(12.5%) 
o9 It is interesring to note that patient with Ca Cervix has an elevated value ofCA 125:::465.5 IU/ml 
~ _ ffistopath report not available ( or not enough sample ) 
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Table 3 :Normal Serum Cal5.3 value at Diagnosis.( <28 U/ml) 
No Patient Diagnosis CA15.3 Wad Age Race Histopath 
At Diagnosis Report.~ 
1. GCJ Ca.Breast 14.7 0/G 38 c 
2. FCL CaBreast 22.4 RT 52 c 
"" MMA Ca(L )Breast 17.3 RT 67 M j. 
4. RZ Adv.Breast Ca 28.2 3s 53 M 
5. NNM Adv.Breast Ca 13.4 SOPD 63 c 
6. zy Ca.Breast 18.3 RT 62 M 
7. ZAR CaBreast 39.1 RT 41 ~1 
8. SED Brain Lesion 30.5 7u 44 Ivf 
9. SH Fibroedenosis 8.9 SOPD 20 M 
10. ZS Ca.Breast 21.1 RT 39 M 
lL CBCK CaBreast 13.8 On co 79 M 
12. AE CaBreast 18.0 On co 75 M 
13. HD CaBreast 11.3 RT 61 ?vi 
14. ZI Ca Breast 16.4 On co 64 1vf 15. CYY CaBreast 9.3 3s c 16. NJ Ca Breast 16.4 SOPD 40 M 17. roAN CaBreast 1.17 RT 43 M 18. SD. CaBreast 13.4 RT 42 M 19. YA CaBreast 8.5 On co 77 I\tl 20. HAJt CaBreast 43 RT 43 M 21. MD CaBreast 53 RT 53 l\I 
Statistic Report : 
N=35 
22xl00/35 = 22{62.8%) 
confirmed Ca {Histopath Report) but low Cal 53 : 3x100/35 = 3 (8.57%) 
Comments: Patients on treatment (monitoring) 
~ Histopath report not available. 
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Table 4 :Serum CA 153 : Above Cut ( >28U/ml) 
No Patient Di~onosis CA 15.3 \Vad Age Race Histopath 
At Diagnosis Report 
L SA Ca. Breast >120.0 3U 2s lvl 
2. s~ CaBreast 53.6 SOPD 2s M 
3. RE CaBreast 77.8 RT 47 M 
4. cs CaBreast 94.3 3s 48 Ivl 
5. LZH Ceroblast 41.5 3U 40 M 
6. ZAH Breast Abcess >120.0 3U M 
7. :MES CaBreast >240.0 3s M 
8. RZ Ad.Breast Ca 28.2 3s 53 M 
9. ZAR CaBreast 39.1 RT 41 1vi 
10. SED Brain Lesion 30.5 7u 44 :rvr 
11. NA.l\A BreastCa 44.4 SOPD - Nl 
12. l\1NS** MassL.Avilla >240 4s 37 :rvr 
13. HXL Ca. Breast >240 RT 49 c 
Statistic Report 
N=35 
13xl00/35::::: 13(37.1%) 
Confirmed Ca (H:istopath Report ) 
3xl00/35 = 3 (8.5%) 
1 ~fale Patient Elevated Ca 153 : l\1NS 
Ixl00/35 = 1(2.8%) 
.. Histopath report not available. 
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R~ulta: 
Table 5 : CA125 Lev~!s (N=56 ) 
Cancer Patients -confirmed BFE report 
CA 125 Below cut of value: 8 (14.3%) 
CA 125 Above cut of value : 7 (12.5%) 
AU Patients 
CA 125 Below cut ofvalue·: 34 {60.7o/c) 
CA 125 Above ~t of value :22 (39.2%) 
Table Sa :~_CA125 level in patient diagnosed with ovarian cancer (N=15) 
<35 U/ml = 8/15x1000/o = 53.3% 
>35 U/ml = 7/15x100% = 46.7o/o 
TabUe 6 : CA 15.3 Level3 ( N=35 ) 
Cn:acer P~timts -eonfi:rmed l:IPE report 
CA15.3 Below cut of value: 5 (14.3%) 
CA 15.3 Above cut ofyalue: 3 (8.5%) 
AU Pat!emrls 
CA15.3 Below cut of value: 22 (62.8%) 
CA 15.3 Abovecutofvalue: 13 (37.1%) 
Table 6a: CAl 53 Level in patient diagnosed with breast cancer 
<28 U/ml = 5/8x;l00% = 62.5% 
>28 U/ml = 3/8 xlOO% = 37.5% 
fh~.n1tby sebject Nomutl Value (Table 7) 
TEST 
CA153 
CA125 
N 
17 
17 
X 
5.25 
9.28 
SD 
4.55 
3.94 
Healthy subject Distribution Rang~ {normal valu!e). 
Additional information included : 
Table 8 :Statistic oftnnumr markers done at Chemical Pathology L-abornt{)ry Unive-rsity 
§ahlls f.i'.d.a]iuysia Kubun1g l~tll'Wllll K~~~ultaat. 
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J . Table 6 
1. AJ17121 Left Breast: Th"'FJLl'.MTll~G DUCTAL C.ARCll~01vfA 
(GRADE 11, lVlODlFIED BLOOM ANTI RICHARDSON). 
2. B059i75 Left ova..ry - Papillary .Serous Cystadenocarcinoma vvith 
deposits in myometrium,, parametritun and the omentum. 
3. I 031907 · Gastric (antral) biopsy: W1TIITN' NORMAL 
4. Bl19648 Left Ovarian Cyst: Th1MATIJRE 1ERATOMA (GRADE 11, 
NORRIS CLASSlFICATION) 
5. B122511 A: Right Ovary :. 'MATURE C¥STIC . 
TERi\.TOMP .. ;O:N.ffiNTUM: METAST.A"'TIC ENDODER1'.L.A~ 
SINUS TlJ.tviOUR 
6. A810975 A: Right Ovary: COlvfP ATIBLE \VITH A BENIGN 
~ 
HAEMORPJIAGIC UN1LOCULAR CYST· 
B: Left, Ovarian Mas~:, CLEAR CELL C~C:WOMA, ·yv JlH 
CAPSULAR n-N ASION· . . . 
, . . C; Omentum: NO :tviALIGNANCY SEEN. 
. ,, .. ·•·. 
Tumour From Right Lateral Aspect Of Vault: RECURRENT ,.,::7. A806853 
SEROUS PAPILLARY ADENOCARC1NQMA. . . 
0 B113254 A: 'Mass': 11ETASTATIC.PAP1LLARY SEROUS CYST o. 
' 
ADENOCAH.CINOM.A 
B: 'Right" Ovarian Ma$s: PAPILLA..'R.Y SE~OUS CYST 
ADENOCARCINOI\1A (\A/ITH CO:t\TJRALATER_J\L 
OV APJAN TUM bUR 1v1ETASTASES) 
Uterus: LEI01'v1Y01v.r.A. . . 
9. B126154 Aim_endix: SUPPURATIVE APPFNTIICITIS . 
10. AS3536o Endometrial Samplin,g:· INADEQUATEMATE.RlALFOR . 
INTERPRETATION.· 
11. B111064 A: Cervix: CHRONIC CERVICITIS 
Uterus: SEROSms 
B: Peritoneal Biopsy: NON SPECIFIC CHRONIC 
JNFL.A1.llviATION .. 
C: Peritoneal Nodule:· GR..A.Nl.JLATIONTISSUE 
. . D: Omenttun: Cf.IH.Of-ITC 1'-lON SPECIFIC ThtlFLftJ\1lVIATION 
• • "'\ o • 1 
E: Left Ovary: JUVENILE GRMTTJLOSA CELL TU1v10UR 
-
.A040170 Ltft breast - Invasive Ductal Carcinoma (NOS - ~rade IT) 12. (Bloom and Richardson). 
.. ~ 
: 
Endometrium: EARi Y 'SECRETORY .PFL~E 
-...., A834444 Left breast) m.astectorriy : .INFILTR,A.TIN'G DUCTAL l.J. . Ci..RCIN01v1i\. (l'J03/l~ST -r:lTE) 
(GRADE II I MOD. DIFF.) 
"'"14. A091734 Ereast, Right Lovver Inner Quadrantectomy: DUCTAL 
- CAF~CINOMt\. IN SITU, CF.IBRlFORl\1 TYPE, \VITH 
l\.flNTh1AL il'N .ASI<?N.·ESTROGEN H.ECEPTOR STATUS 
.. :NEG.A. TIVE . . . 
~ A052142 Ri£bt Breast Lump: INFIL TR~ TING DUCTAL 1 5. 
.__ 
11 
CARCINOW~ (NOS) 
-
POORLY DlfJ:; .ERENTIA TED \VITH 
ll'f"V'OLVE!vfENT OF THE 1v1ARGll\fS. (BL901YI 
M1J RIC:H!iliDSON'N GRADING) 
A: Right Mastectomy Specimen: RE111\TANTS OF 
11.ALIGNANCY SEEN (SURGICAL M.L\RGThTS ARE fREE 
OF1UMOUR) 
16. Bll5178 A: Left Ovarian Mass: SEROUS CYSTADENOMA AND 
SEROUS CYST ADENOFIBROMA OF LOW GRADE 
MA.LIGNA."NT POTENTIAL. 
B: Uterus, Cervi"< and right ovary: . E.NDOCEP ... VICAL POLYP:) 
END01VIETPJAL POLYP M-ID A TINY SUBNIUCOSAL 
. LEIOMY01:'JA. NOIDv:fALF.AiiOPW~:ruBES (R &L) 
(RlGJ¥) OV .ARY: A ~OCUS OF HYPERPLASTIC 
STRO!v1AL NODULE 
C: 01nental Tissue: NO 1UMOUR DEPOSIT 
17. A886276 Tntcut Breast Biopsy: INFILTRATll\TG.CARCINOMA 
18. A077547 Right Breast:· INF~TRATING DUCTAL CARCillOMA, 
I-ITGH GRADE.(BLOOD AND RICHARDSON) ~TH · 
LYMPH NODE INVOL VEiviENT 
19. B~20320 A: tvruCINOUS CYSTADENOMA- RIGHT ·OVARY 
B: NORMAL OV ft..RL.A.N TISSUE - LEFT OV AA Y 
C· 
' 
NOIDIIAL FIBRO FATTY TISSUE= 011EN11Jl\,f 
20. A214923 Endoll1etrial Pipelle: INADEQUATE FOR IDSTOLOGICAL 
DIAGNOSIS 
.. 
Right Ovarian Cyst: E:NTION.iETRlOTIC CYST 
21. A923523 Mastectomy Specimen: INFILTRATING DUCT 
CARCWOMA. 
·22. ·B150212 Left Ovarian Cyst: ENDO:N.fETRIOTIC CYST 
23. B150828 At>pe.ndix: EARLY APPENQICITIS 
24. Al50693 Pipelle: NON REPRESENTATIVE S~:t\..1\APLE . .. 
PJght Ovarian Tumour: ·:rv1UCINOUS CYST ADENOMA 
Uterus: ADENO~vfYOSIS 
. Fibroid: .ADENOMY01v1A 
25. B150693 uastric Biopsy: \V lliffi"'T NORMAL LllviiTS 
26. B152122 A: Omentum: CONGESTION AND MILD ACUTE 
INFLA1v.[N.[.A. TION · 
B: R.; rrb.L Qvqria n rys•· 111Jf"1frJQT T.:J C'TC"T' I'I~IJ··T01v1'' -· 't;1 •.L tl• •~-' '---' ~ •. - ..1. '--" ' '-' ·.lUl..£ J.'i .t·}. 
27. 
-
12 
J 
! 
-
-
r-
-
,.... 
TABLE 7 
PREUMINARY REPORT OF : HEAl THY SUBJECT DISTRIBUTION RANGE 
TU;\\OUR MARKER TEST : CA15-3 (BREAST) 
KIT (EUSA) : CA125 (OVARIAN) 
SCREENING TEST FOR HEAL THY SUBJECT : CEA 
CA15-3 CA125 
Ref. Value Ref.Value 
NO. LAB# < 28 u/mL < 35 Iu/ml 
~-
1. 1. 3.18 (·) . 4.86 (-) 
2. 3 7.30 (-) 15.7 (-) 
3. 4 1.72 (-) 1.50 (-) 
4. 5 1.33 (-) 4.17 (-) 
5. 10 ·12.3 (-) 27 .. 7 (1) 
6. 8 3.9 (-) 2.04 (-) 
7. 6 15.0 ( .. ) 16.7 (-) 
8. 4 . 7.48 (-) 5.25 (-} 
9. 13 4.23 (-) 22.5 (-) 
10. 15 9.76 (-) 5.08 (-) 
11. 12 4.31(-) 25.2 (-) 
12. 17 0.86 (-) 2.10 (-) 
13. 18 1.12 (-) 2.10 (-) 
14. 19 1.30 (-) 6.57 (·) 
15. 20 3.63 _(-) 12.2 (-} 
16. 21 0.22 (··) 2.70 (-) 
17. 7 11.7 {-) 1.49 (-) 
N 17 17 
X 5.25 9.28 
Sl> 4.55 8.94 
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DISCUSSION : 
- . 
Comments :( Summary Reports ) 
1. Cases of high valueof CA125 ;22(39 .2 %)and CAl 5.3 , 13(37 .1 %)belong to non cancer group would 
predict that patients tnay be at benign stage and not at malignant stage. · 
2. Significantly high values ofCA125; 7 {12.5%)were found in ovarian canceas patients as confirmed by 
J-:WE report. 
Significantly high values ofCA15.3; 3 (8.5%) were found in breast cancer patients as confirmed by 
HPEreport. 
3. One case of elevated CA153 of male patient was fotmd, 1{2.8%) dwing screening at diagnosis.This 
shows that even male patient is prone to have breast cancer. 
4.0vmll N=91 patients are predominantly 1\-Ialays 86 (94.5%) and 5 (5.5%) are Chinese. This may reflect 
the dominr""lt Malay population in Kelantan. Their age ranges from 18-61 yrs old .. 
19 
Condusicn 
1. Elevated Ca 125,22 out oft39%) and Ca 153, 13 out of(37.1%) were considered imminent as our 
results show that it was possible to detect both cancers using ELISA technique . 
2. Elevated level of serum CA125 above cut of value was seen in 39% of patient (22/56) diagnosed with 
ovarian cancer and 
Elevated level of serum CA 153 above cut of value was seen in 37.1% patient~ (13/35) diagnosed with 
breast cancer. 
3. This study however was not able to get a full histological report of patients and thus correlation of 
the tq_mour markers with the stage of tumour was not able to be executed accurately. 
However an indication of its usefulness in aiding diagnosis of the respective cancers cannot be 
dismissed. \Ve can see a high level ofCA 125 in patients with ovarian tumour e ovarian cyst (Table 
2), ranging from 53.7 to 467.8 U/ml. 
4. Our future stl.tdy will include l)a correlation study of serum CAl 53 s CA 125 in both breast cancer 
& ovmian cancer patients. 
11 )a correlation study of serum CEA vesus serum CA15 .3 2: CA125 
in both diseases :ie breast and ovaria..tl cancer. 
20 
Suggestion And Review : 
l.Since due t~ short period of time and limited funds this project would be versatile if more subjects being 
included and to study the clinical data of the patients with recurrent disease including the site of origin of 
the disease,histology, Th~J.f. stage CAI25 and CAI5 .3 level at the initial diagnosis after ~reatment and at 
recurrence. 
And also the mean lead time between the elevation of the marker level and the clinical diagnosis of the 
recurrent disease . 
2. Also other tumour markers assay such as correlation study between CA15.3 and CA27.29. 
Ca27.29 seems more sensitive than CA15..3 atJ.d con..firm that CA27.29 may enter the diagnostic 
armentarium of tumour marker that are effective for breast cancer. (7) 
3. To study in combination with CA125,CA15.3 wheather useful in early detection of relapse of ovarian 
camcer. 
21 
References: 
!.Leslie C. Lai : Analytical Considerations and Clinical Utility of Serum Tumour Markers 
Malaysian Journal of Clinical Biochemistry Vol.3,Number I August 2000. 
2. Jean-~fichel Bidart: Kinetics of Serum Tumor Marker ~oncentrations and Usefulness in Clinical 
Monitoring 
Journal of Clinical Chemistry 45:10, 1695 .. 1909 (1999} 
3.Yasmin Anum : JustificatiQn For setting Up Of Tumour Markers Laboratory/Centre At The Department 
Of Chemical Pathology. 22 Sept 1999 (Memo) 
4. TECO Reagent Pamphlet :Breast Cancer Antigen Ca15.3 Enzyme Immunoassay Test Kit 
Catalog Number : BC ·1 015 
5. TECO Reagent Pamphlet : Cancer Antigen CA125 Enzyme Imntunoassay Test Kit 
Catalog Number : BC 1013 
6.Perbandingan Keputusan Analisis "Tumour Markers" melalui Dua Kaedah iaitu ELISA Dan ECL 
Technologi _ Laporan Projek Penyelidikan DTM:P 35/98 
7. M. Gion, et all - Ca21.21 : a valuable marker for breast ·cancer management. A confirmatory 
multicentric study on 603 cases 
European Journal Of Cancer 37 (2001) 355-363 
8 T Me er and GJS Rustin- Rol-e of tumour markers in monitoring epitheliual ovarian cancer. 
· · y Bdtish Journal of Cancer (2000) 82 (9), 1535-1538. 
TECO Reaaent Pamphlet : TECO CEA microwell Test Kit Enzyme link immunosorbent assay (EUSA). 9. 0 . 
22 
ATTACHMENI'S 
23 
.·.,.. ~- . -
• ... ·.:. 
-- . 
...... 
.. 
·rq;'t.'W"*¥~·#H&&¥§§6¥¥4Wfiit#*-#?N*Wi¢'f.M'fd<%§AA$Mi#·-i-44M%'¥if?§lt!l'q .. 1#!@ijfflrt;;p@!§Ad¥fi¥1'l'ffl'ii6 £;~.&@@ii!ilfii#C#i'$?AA?iNtl:;;s;c:@<§f§¥it4Wi 
CANCER ANTIGEN CA125 ENZYME IMMUNOASSAY TEST KIT. 
· Catalog Number: BC-1 013 ·=~:: ... · ..... ~, • .. ·. :· .... -:·
1
f . "' · 
Enzyme Immunoassay for the Quantitative 
Determination of Ovarian Cancer Antigen 
CA125 in Human Serum 
.· 
FOR IN VITR~ DIAGNOSTIC USE ONLY· 
Store at 2 to soc. 
PROPRIETARY AND COMMqN NAMES 
cA 125 Enzyme lmmunq~ssay 
INTENDED USE 
For the qu~ntiiative determination of the Cancer ,A.ntigen CA125 
ccncentrat:on in human serum. 
INTRODUCTION 
Cancer Antigen 125 {CA 125) is a surface antigen associated with 
epithelial' ovarian cancer. In ·serum, CA 125 is associated with a high 
molecular weight glycoprotein. Published .studies have indicated that 
elevated serum CA 125 levels can be found in individuals with 
serious endometroid, clear-cell and undifferentiated ovarian 
carcinoma. 
The serum CA 125 r.oncentra!ion is gr~ater than 35 units per ml in 
60% of women with ovarian cancer and >80% of patients with 
disseminated ovarian cancer. The serum CA 125 is elevated in 1% 
of normal healthy women, 3.% of normal healthy women ~ith benign 
ovarian diseases, 6% of patients with non-neoplastic conditions 
(including but not limited to ~rst trimeste; p~eg.~ancy, m~ns~uaUon, 
endometiiosis, uterine fibrosis, acute sa,phmg1t1s, hepatic d1seases 
and inflammation of peritoneum, pericardium ?r pleura). Serial 
determinations of serum CA 125 as well as pelvic examination 
increase the test specificity. Serum C~ 1.25 ~o~centration may be 
us"'ful in monitoring treatment and d1stmgU1sh1ng between good 
re;ponse to treatment and progressive malignant disease with poor 
therapeutic _response. To ?gte, C~ 125 is the most sensitive marker 
t 'dual epithelial ovanan cancer. CA 125 may also ~e elevated 
,or res1 . d t · d in patients with lung, cervical, fallopian tube, an u enne cancer an 
endometriosis. · 
n·-·l!''r·lr:~J ~or:: ·r·~·r TE·ST ( h. \l v I .... ~ • ' • ~ ~ 
. The CA 125 ELISA test is based on the principle of a soli~. phase 
I. k d ·1mmunosorbent assay. 1 ~ The assay system uuhzes a enzyme- m e · d' •· t t' · 
1 
t'body directed aga1nst ·a IStlnC an 1gemc 
monocl.ona, anth1.e 1.ntact CA 125 molecule is used for solid phase determrnanl on · ) A .bb't r CA125 
immobilization (on the mi9rotit~r wells :d r(aHRIPOa)n.l-. th 
. , . ted to horseradish perox1 ase , IS Jn e an~body conjuga . ate solution. The test sample is allowed to 
ant1body4 enzyme conJ~9 tw ~;bodies fesulting in the CA 125 
t . It usly With the 0 anu I . reac s1mu a~eo . hed between the solid phase and enzyme-
molecules bemg sandwJc . .. . bat: on at 37oc the wells are 
I. r d t'b d' After a 3-hour m~.,;u I ' mKe an 1 o 1es. bound labeled antibodies. A 
washed with water to. re~~~~ ~~d incubated -for 20 minutes, 
solution of H20VTMB 15 f bl e color. The color development resul~ing in the developmen~ 0 a u · 
'· ... . - :: . :-:: 
. : .. . : .. · ...... : :.··. ·:.: . } 
is stopped with the addition: of 3N HCI changing. the ·color to yellow. 
The concentration of CA125 is directly proportional to the color 
intensity of .the test sample; . Absorbaoc.e is . measured 
spectrophotometrically at 450 nm. · .· .. :.·. _ 
.. . REAGENTS .. 
Materials provided with the kit: _ 
D Murine Mon9clonal anti-CA125 coated microliter plate 'with 96 
wells. · 
• Enzyme.Gonjugate Reagent, 13 mi. . . 
e . CA 125 reference standards .con.taining; 0, 15, 50, 100, 200, 
and 400Uniflml of CA 125, 1 ml each, ready' to use. 
o Color R~agent A, 1.3ml. · · 
o . Color Reagent 8, 13ml. 
• ~top Solution (3N HCI), 10ml. 
Materials required but not. provided: 
o Precision pipettes and tips, 0.1 ml, 0.2ml, 1 ml, and Sml. · 
o Disposable pipette tips.~ · · 
o . Distilled water. 
e Glass tubes or flasks. to mix Color A Reagent and Coler 
Reagent 8 solutions. 
o · Vortex mixer. 
o Absorbent paper. or paper towel. 
o · Microliter plate reader~ 
o Graph paper. 
SPECIMEN COLLECTJON AND PREPARATION 
Serum should be prepared from a whole blood specimen obtained 
by acceptable medical techniques. This kit is for use with serum 
samples without additives only. 
STORAGE OF TEST .KIT AND 
INSTRUMENTATION 
Unopened test kits should be stored at .2~aoc upon receipt and the 
microliter .plate should be kept in a sealed bag with desicaants to 
minimize exp<)sure to damp air. Opened test kits will remain stable 
until the expiration da,te shown, provided it is stored as described 
above. A microtiter plate reader with a bandwidth of 10nm or less 
and an optical density range of 0-2 .00 or greater. at 450nm 
wciv~iength is acceptable for u~e in ab6orbanea mea~urcme:1t. 
REAGENT PREPARATION 
1. All reager1ts should be brought to roo'm temperature {18-25°C) 
before use. . - · · 
2. To prepare HzOiTMB solution, make an. 1:1 mixing of Color 
Reagent A with Color Raagent 8 up to 1 hour before use. Mix 
gently to ensure complete m.ixing . .The prepared H20v'TMB 
reagent should be made at least 15 minutes before usa and is 
stable at room temperature in the dark for up to 3 hours. 
Discard excess aftei usa. 
ASSAY PROCEDURE 
1. Secure the tesired number of coated wells in the holder. 
Dispense 100J.1! of CA125 standards, specimens. and controls 
into the appropriate wells. . 
2. Dispense 100~ll Enzyme Conjugate Reagent into each well. 
3. Mix gently for 30 seconds. It is .very important to have 
complete mixing in this setup. 
4. · Incubate at 37°C for 3 hours. 
e Prepare HzOfTMB substrate 15 minute~ before use. 
5. Remove the incubation mixture by .e.mptying the plate content 
into a waste container. 
§.: Rinse ar:d empty the micrcHiter plate 5 times with distilled or 
deion;zed water.-(P/ease do not use tap water.) 
'· Strike the microliter plate sharply onto absorbent paper or 
paper towels to remove all residual water droplets. · 
8. Dispense 200J.1I of HzOVTMB solution into each well. Gently 
mix for 10 seconds. Incubate at room temperature. in the dark. 
for 20 minutes. 
9. St()p the reaction by adding SO~il of Stop Solution to each well. 
10 .. Gently mix for 30 seconds. It is important to.make sure that 
all the blue color changes to yellow color completely. 
11. Read the optical densily at 45Cnm with a microliter plate reader 
.within 30 minutes. 
. CALCULATION OF RESULTS 
1. Calcuiate the average absorbance values (A450) for each set 
cf referenr.e standards. contrq!, and samples. 
2. Construct a standard curve by ptotting the mean absorbance 
obtained for each reference standard against its concentration 
in U/rnl en linear graph paper. with absorbance on the vertical 
(y) axis and conc~ntration on the h~~izontal (x} axis.· 
3. Using the mean absorbance value for each sample, determine 
the corresponding concentration of CA 125 in U/ml from. the 
standard curve. 
EXAMPLE OF STANDARD CURVE 
Results of a typical standard run with optical density readings at 
450nm shown in the Y axis against CA 125 concentrations s·hown in 
the X axis .. This standard curve i~ for ·the purpose of illus~ation only, 
and should not be used to calculate unknowns. Each user should 
obtain his or her own data and standard curve in each experiment. 
..--· 
CA125 varues (U/mi} I Absorbance (45.0nrn) 
0 0.010 
15 0.105 
50 0.347 
100 .. 0.703 
2£)0 1.411 
400 2.437 
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EXPECTED VALUES AND SENSITIVITY 
H~althy worn~~ ~re exp·ecte~ to have CA 125 assay values belo1 
U mi. . The. mmJmum detectable concentration of CA125 in 
assay IS est1mated to be 5 U/ml. 
1. .LIMIT~TIONS OF THE PROCEDURE R_:ltable and reproducible results will be obtained when 
~;:~ pr~ced.ur~. is ~a.rried out with a complete understan 
lab tpackage .'nserL mstruetions and with adherence to ( ora cry pract1ce. . · · 
2... The wash procedure is crit' 1 1 • p~or precision and falsely ~~=\;a~~ufficJent washing ~ill res 
3. . Tne results obtained from the us ab~~r?an~e readings . 
?nly as an adjunct to other ~i~r th~s. kJt shoukJ be I 
tnformation avaifable ·to the h . . gnostic procedures 
. · P ysrc1an. 
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BREAST CANCER ANTIGEN CA15-3 ENZYME IMMUNOASSAY TEST KIT 
1 Catalog Number: SC-1015 
to the color intensity of the test s.ampt~;!. Absorbance is measured 
spectrophotometrically at 450 nm. - : · · ·. ' ·: . 
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Enzyme Immunoassay for the Quantitative 
. Determination or Breast Cancer Antigen 
. CA 1.5·3 in Human Serum . 
FoR IN VITRO QIAGNOSTIC .USE ONLY 
I Store at 2 to soc. . PROPRIETARY AND COMMON NAMES 
CA 15-3 Enzyme lmm1Jnoassay . I . INTENDED USE I 
For the quantitative determination of the Cancer Antigen ·cA15-3 
concentration in human serum. · I INTRODUCTION . 
Breast cancer is the most common life-threatening malignant lesion 
in women of many developed countries today, with approximately 
1180,000 new cases diagnosed every year. Roughly half of these newly diagnosed patients are node-negative, however 30% of these 
cases progress to metastatic disease. . 
I There are a n~mber of tu~or markers that can ·help clinicians to id~ntify and d1agnose wh1ch breast cancer patients will have 
aggressive disease and which w.ill have an indolent course. These 
r 
markers includa estro§en and progesterone receptors, DNA ploidy 
and percent-S J.!llase profile, epiderm~! growth factor receptor, 
HER-2/neu oncogene, p53 tumor suppressor gene, cathepsin D. 
proliferation markers and CA 15-3. CA 15-3 is most useful for 
( monitoring patients post-operatively for recurrence, particularly 
metastatic diseases. · 96% of patients wit:, local and systemic 
recurrence ·have elevated CA 15-3, which can be used to predict 
' 
recurrence earlier t~an radiolog~cal and. ~linical. criteria. A 25% 
increase in the serum CA 15-3 IS assoctated With progressio·n. of 
carcinoma. A 50% decrease in serum CA 15~3 is associated with 
response to treatment. CA15-3 is more sensitive than CEA in early 
! detection of breast cancer recurrence. In comb_ination witn CA 125, 
CA15-3 has been shown to be useful in ~arly detection of relapse of. 
ovarian cancer. CA 15-3 levels .are also increased in colon, lung and 
I . 
' hepatic tumors. 
PRINCIPLE OF THE TEST 
·1 he CA 15.3 I:: LISA test is based Ul} the princip:a of a soH d. fhase 
e I. k d immunosorbent assay. The assay system utilizes a nzyme- 1n e . d' t' t t' . 
1 m 1 1 antibody directed aga1nst a 1s 1nc an 1gemc onoc on a · 
1 
• d ~. I'd h 
d t . t · the 1·ntact CA 15-3 molecu e 1s use ,or so 1 p ase e erm1nan on . . 
· b'l' t' {on the micro titer wells). A · rabb1t an t1-CA 15-3 
1mmo 1 1za 1on . 'd (HRPO) . . th 
... t'b d . gated to horseradish perox1 ase IS 1n e an I 0 y conJU ·.• L' • 
•:b d _ e con1·ugate solul1on. The test sampl~ IS allowed to anu 0 y enzym 'b d' It' · th CA15 3 
react sequentially. with the two antr o 1es, r~su 1ng In e -
molecules being sandwiched between the sohd phase ?nd e~zyme­
linked antibodies. After two separate 1-hour mcubat1on s,eps at 
37oc, the wells are washed with wa~er to remove ~nbound labeled 
antibodies. A solution of H20Vffvl8 IS ad?ed and Incubated for 20 
rninutes, resulting in the developme~t. o. a blue color. The col0r 
deve!opment is stopped with the add1t1on of 3N HCI changing the 
, Color to yellow. The concentration of CA 15-3 is directly. proportional 
I 
REAGE~rrs:· 
Materials provided with the kit: · · . 
e Muriine Monoclona~ Anti-CA15-3 coated microHte~ plate ·with 96 
wells. 
o Sample Diluent, 100 mi. 
., Enzyme Conjugate Concentrate (22x), 1.0 mi. 
e Enzyme Conjugate Diluent, 21 mi. . . 
a. CA 15-3 reference standards, containing 0, 15, 30, 60, 120, and 
240 UniVml. Liquid. 1 s~t. These standards have been pre-
diluted 51-fold. Please do not dilute them again. 
Q Color Reagent A, 13 mi. 
o. Color Reagent 8, 13 mi. 
• Cl Stop Solution (3N HCI), 10 mi. . 
Materials required but not provided: 
o Precision pipettes and tips, 0.1 ml, 0.2 ml, 
1 m.l, and 5 mi. 
• Distilled water. 
o Disposable pipette tips. . 
• Glass .tube or fiask to mix Color Reagent A and Color Reagent 
8 solutions. 
• Vortex mixer. 
o Absorbent paper or paper towel. 
• A mi9rotiter plate reader at 450nr:n wavelength, with a 
bandwidth of 1 Onm Oi.less an~f- a:n optical" density range of 0-2 
00 or greater. · · 
e Graph paper. 
SPECIMEN COLLECTION AN.D PREPARATION· 
Serum should be prepar~d. from. a whole blood specimen obtained 
by acceptable .medical techniques. this kit is for use with serum 
sampt~s without additives only. · 
STORAGE OF TEST KIT 
. .AND INSTRUMENTATION 
Unopened test kits should be stored at 2-eoc upon receipt and the 
microtiter plate should· be kept in a segled bag with desiccants to 
minfmize exposure to damp air. Open~.d test kits wilr remain stable · 
until the expiration dat~ shown, provided it is stored as described 
above. A microtiter plate reader with a bandwidth of 10nm or less 
and an ~plical density range of 0-2 00 or greater at 450nm 
wavelength is acceptable for use in absorbance measwement. 
· . REAGENT PREPARATION 
1. All/eagents should be allowed. to reach room temperature (18-
25 C) before use. 
2. To prepare working CA 15-3 Conjugate Reagent, add the 
entire 1.0 ml of Conjugate Concentrate (22x) to 21 ml of the 
Enzyme Conjugate Diluent '(1:21 dilution) and mix well. The 
diluted Enzyme Conjugate Reagent is stable at 4° C for at 
.least 4 months. 
3. To prepare ~2021TMB solution, maKe a 1:1 mixing of Color 
Reagent A With Color Reagent B up to 1 hour before use. Mix 
gently to ensure complete mixing. The prepared H20z/TM8 
reagent should be made at l~ast 15 minutes before use and is 
stable at room temperature in the dark for up to· 3 hours. 
Discard excess after use . 
. ASSAY PROCEDURE 
'-- 1. Patient serum aryd control serum should be diluted, 51 
·told, before use. Prepare a series of small tubes (such as 
1.5 ml microcentrifuge tubes) and mix 20 pi serum with 1.0 
··-. 2. 
. ml Sample Diluent. PLEASE DO NOT DILUTE THE 
STANDARDS. 
Secure the desired number of coated weJis in ·the hoider. 
Dispense 200 ~I of CA 15-3 standards, diluted specimens, and 
diluted controls into the appropriate wells. Gently mix for 10 
seconds. 
Incubate at 37°C for 1 hour. 
4. Remove the incubation mixture by emptying the_ plate content 
into a '.vaste container. . 
5. Rinse· and empty th~ microliter plate 5 times With dis tiffed. or 
deionized water. (Please dq not use tap water.). 
~.,.. 6. Strike the micrQtitei platE? sharply onto. absorbent paper or 
paper towels to remove all residual water droplets: 
·· 7. Dispense 200~1 of Enzyme Conjugate Reagent into each well. 
Gently mix fer 10 seconds 
8. Incubate at 37°C for 1 hour. 
9. Remove the contents and wash the plate as described in steps 
r-5-rabove. ( 5 - f.D) 
e Prepare HzOflMB substrate 15 minutes before use. 
I 0. Dispense 200 J..li H202fTMB substrate.reagent into each well. 
Gen Uy mix for 1 0 seconds.· 
1 1. Incubate at room tempe:ature in the dark for 20 minutes. 
12. Stop the reaction by adding SOpl of Stop Solution to each welL· 
13. Gently mix foi 30 seconds. It is important to make sure thac 
all the blue color changes to yellow color completely. 
14. Read the optical density at 450nrn with a microtiter plate reader 
within 30 minutes. 
CALCULATtON OF RESULTS 
1. Calcuiate the average absorbance values (A450) for each set 
of reference standards, control, and. samples. 
2. Construct a standard cu·rve by plotting the mean absorbance 
obtained for ead1 reference standard against its concentraiion 
in U/ml on linear graph paper, w1!h absorbance on the vertical 
{y) axis and conc~ntration on the horizontal (x) axis. 
3. -Using the mean absorbance vatue for each sample, determine 
the corresponding concentration of CA 15-3 in ng/ml from the 
standard curve. · 
EXAMPLE OF STANDARD CURVE: 
Results of a typical standar.d run with optical .density readings at 
450:arn s!1mvn in the Y-~!xis 2gainst C.l\15-3 concentrations shown in 
the X axis. This standard curve is for the purpose of illustration only, 
and should ·not be tJsed to calculate unknowns. Each user should 
obtain his or her OV{n data and standard curve: 
CA 15-3 Values {U/m1} Absorbance (450 nm) 
0 0.021 
15 0.425 . 
30 ··0.693 
60 1.214 
120 1.956 
: 240 2.845 
~ .:. 
.r •, 
e· 3 
c:: 2.5 0 
ll) 
~ 2 
Cl.l 
CJ 1.5 c:: 
ro 1 .c 
... 
0 0.5 Ul 
.c 
c:t: 0 
0 50 100 150 200 250 
Cone. ·of CA15·3 (U/ml) 
EXPECTED VALUES'AND SENSLTIVITY 
Healthy women are expected to ·have CA 15-3 assay values beluw 
35 U/~1. .T~e minimur:n d~tectable concen!ration of CA 15-3 in this 
assay ts estlmat~~ to be 5 U/ml. 
1. 
2. 
3. 
LIMITATIONS OF THE PROCEDURE 
Reliable and reproducible results will be obtained when t ! 
as_say procedure is ·carriE:!d out with a complete under~tandina 
of the package insert instructions and with adherence· to good 
laboratory practice. · 
The wash procedure is critical. Insufficient washing will result 
~cor precision· a~d falsely elevated absorbance readings. 
I he results obtamed fro~ the use of this kit shol!ld be us. 
.only as an adjunct to other diagnostic procedures 8, 
information available to the physici~n. 
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